



## Travelan and Protectyn Are Now Available For Sale in China

**Melbourne, Australia, 16 June 2016:** Australian microbiome biopharmaceutical company Immuron Limited (ASX: IMC) is pleased to announce that QBID has placed its first orders for both Travelan and Protectyn to ensure they have stock of both products now that they are available for sale in China from the JD.com website.

Immuron's CEO, Mr. Thomas Liquard commented:

*"As we promised shareholders in our announcement on 9 May 2016, Travelan and Protectyn are now available for sale in China. We have been working hand-in-hand with our Chinese e-commerce partner, QBID, to ensure that we met our aggressive launch timelines.*

*Given the recent high demand from China for Australian and New Zealand products, ensuring that our products were available for purchase by Chinese consumers was critical for the Company.*

*We look forward to watching this new high-growth market further expand the demand for Travelan."*



### **Company Contact:**

Thomas Liquard  
Chief Executive Officer  
AUS Ph: +61 (0)3 9824 5254  
thomasliquard@immuron.com

### **Immuron US Investor Relations:**

Jon Cunningham  
RedChip Companies, Inc.  
US Ph: +1 (407) 644 4256, (ext. 107)  
jon@redchip.com

### **About Immuron**

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers' diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: <http://www.immuron.com/>

**Forward-Looking Statements:**

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.